News | Cardiovascular Ultrasound | June 13, 2016

Calculating Aortic Flow Rate Superior Test for Patient Risk Stratification

Mayo Clinic study finds echocardiography suitable test to evaluate heart function via dobutamine response

ASE 2016, Mayo Clinic study, echocardiography, aortic flow rate, patient risk stratification

June 13, 2016 — Researchers from Mayo Clinic believe they have found a better way to risk stratify some of their most fragile patients.

Patients with reduced left ventricular ejection fraction (LFLGAS) being evaluated with dobutamine, a medically induced “stressor,” to view their heart function at work need special care. Looking at a cohort of these patients, the researchers found that using echocardiography to measure their aortic flow rate was a good predictor for their risk. “Our work highlights, for the first time, the importance of calculating aortic valve flow rate to risk stratify patients undergoing dobutamine stress echo for a low-flow, low-gradient aortic stenosis. We showed that flow rate goes above and beyond contractile reserve, which is what is being used right now, to risk stratify these patients,” said Said Alsidawi, M.D.

Researchers on the study, Low-flow, Low-gradient Aortic Stenosis: Prognostic Value of Flow Rates vs. Stroke Volume During Dobutamine Echocardiography, included Alsidawi, Robert B. McCully, Christopher G. Scott, Sorin V. Pislaru, Patricia A. Pellikka, Mackram F. Eleid, Jae K. Oh, and Vuyisile T. Nkomo from the Division of Cardiovascular Diseases, Mayo Clinic School of Medicine, Rochester, Minn.

This finding could be useful for many clinicians as patients presenting with low ejection fractions (EF) could be exhibiting an early sign of heart failure. These clinicians need good diagnostic options to assess whether valve replacement surgery or other therapies are needed.

Alsidawi presented a poster based on this research during the American Society of Echocardiography 27th Annual Scientific Sessions, June 10-14 in Seattle. This research was submitted as part of the “Valvular Heart Disease” topic area.

For more information: www.asescientificsessions.org


Related Content

News | Cardiovascular Ultrasound

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

Home April 05, 2024
Home
News | Cardiovascular Ultrasound

August 24, 2023 —Royal Philips, a global leader in health technology, highlighted how it integrates AI in cardiac ...

Home August 24, 2023
Home
News | Cardiovascular Ultrasound

July 27, 2023 —UltraSight, a digital health pioneer transforming cardiac imaging through the power of artificial ...

Home July 27, 2023
Home
Feature | Cardiovascular Ultrasound

February 10, 2023 — GE HealthCare, a leading global precision care innovator, announced that it has signed an agreement ...

Home February 10, 2023
Home
Feature | Cardiovascular Ultrasound | By Paul M Bojarski

Sudden cardiac arrest is a complex and challenging medical emergency because it can occur anywhere at any time and is ...

Home August 23, 2022
Home
News | Cardiovascular Ultrasound

August 9, 2022 — Butterfly Medical, an Israeli medical device company developing a novel minimally invasive solution to ...

Home August 09, 2022
Home
News | Cardiovascular Ultrasound

July 20, 2022 — Teleflex Incorporated, a leading global provider of medical technologies, announced the first patient ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Enhanced features on the Philips EPIQ CVx ultrasound system provide a next level photorealistic 3D rendering, making it ...

Home July 20, 2022
Home
Sponsored Content | Videos | Cardiovascular Ultrasound

Automated features on the Philips EPIQ CVx cardiology ultrasound system are helping to bring consistency and speed to ...

Home July 07, 2022
Home
News | Cardiovascular Ultrasound

June 15, 2022 — Cardiawave SA, a deeptech medical device manufacturer that has developed Valvosoft, a revolutionary non ...

Home June 15, 2022
Home
Subscribe Now